GW Pharmaceuticals (NASDAQ: GWPH) is the biggest of the bunch with a valuation already north of $3 billion. This lofty price comes after its success in pivotal phase 3 trials with experimental drug Epidiolex in treating two rare types of childhood-onset epilepsy. With approval of Epidiolex probably looking better than 50-50 after its phase 3 results, GW Pharmaceuticals has an outside chance at generating recurring profits by the end of the decade. Another company that could be worth monitoring is Corbus Pharmaceuticals (NASDAQ: CRBP). The allure and danger of Corbus’ pipeline is that it’s entirely made up of one experimental anti-inflammatory drug, Resunab, which works with the natural cannabinoid receptors found in our bodies to strengthen the immune system while fighting inflammation typically associated with infection or injury. The company has four ongoing clinical-stage trials, a few of which could lead to instant profitability if Resunab is successful. Nonetheless, Spicer’s comments suggest that the Trump administration’s dealings with marijuana will be a departure from Obama’s hands-off approach. Even though we don’t know all of the details yet, signs don’t point to good news for the pot industry or marijuana stocks in general. 10 stocks Medical marijuana we like better than GW Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.